Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
avalglucosidase alfa Phase 3 Results Expected
avalglucosidase alfa • Glycogen Storage Disease Type II
Target Indication
Glycogen Storage Disease Type II
Clinical Trial
NCT04910776Last updated: 12/11/2025
Nexviadyme
Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency).
View on EMA